Twist Bioscience

Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.

Cowen gave the company a rating of Outperform while JP Morgan assigned its shares a Neutral rating.

The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.

Agilent said it has uncovered new and relevant facts in its intellectual property lawsuit against Twist and its Founder and CEO Emily LeProust.

In a proof-of-concept study published in Nature Biotechnology this week, the team demonstrated that it could enzymatically synthesize 10-mer oligonucleotides.

The deals cover the company's synthetic DNA and next-generation sequencing products, including its newly launched target enrichment line.

The company, which recently entered the next-generation sequencing sample prep market, said it has raised $259 million since it was founded in 2013.

At the AGBT conference this week, the DNA synthesis discussed the new capture products and its overall business.

Companies in the life science tools and molecular diagnostics spaces provided updates on their businesses at the 36th annual JP Morgan Healthcare Conference this week in San Francisco.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.